Immunic Reports Completion of Patient Enrollment in P-II CALDOSE-1 Trial of IMU-838 for the Treatment of Ulcerative Colitis
Shots:
- The company has completed the enrolment in the P-II CALDOSE-1 trial to evaluate the efficacy & safety of IMU-838 (10/30/45mg, PO) vs PBO in 263 patients with mod. to sev. UC at 100+ sites in 19 countries including the US & EU. The results are expected in Q222
- The 1EPs of the trial include a composite of PROs & endoscopy-assessed outcome, following 10wks. of induction treatment
- IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the DHODH enzyme. In 2020, the company has reported the results from the P-II EMPhASIS trial of IMU-838 in relapsing-remitting MS that achieved both 1EPs & 2EPs with high significance
| Ref: PR Newswire | Image: WFLX
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
